Identification

Name
Loxoprofen
Accession Number
DB09212
Type
Small Molecule
Groups
Approved, Investigational
Description

Loxoprofen (INN) is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group, which also includes ibuprofen and naproxen, among others. It is marketed in Brazil, Mexico and Japan by Sankyo as its sodium salt, loxoprofen sodium, under the trade name Loxonin, Argentina as Oxeno and in India as Loxomac. It is available in these countries for oral administration, and a transdermal preparation was approved for sale in Japan in January 2006.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Loxoprofen sodiumNDC2M7399S80382-23-6WORCCYVLMMTGFR-UHFFFAOYSA-M
International/Other Brands
Loxomac / Loxonin / Oxeno
Categories
UNII
3583H0GZAP
CAS number
68767-14-6
Weight
Average: 246.3016
Monoisotopic: 246.125594442
Chemical Formula
C15H18O3
InChI Key
YMBXTVYHTMGZDW-UHFFFAOYSA-N
InChI
InChI=1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
IUPAC Name
2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(CC2CCCC2=O)C=C1

Pharmacology

Indication

Loxoprofen is non-steroidal anti-inflammatory medication (NSAID) indicated for pain and inflammation related to musculoskeletal and joint disorders [3]. In addition to its effects on pain, it is an antipyretic and anti-inflammatory medication [4].

Pharmacodynamics

Loxoprofen is a non-selective inhibitor of cyclooxygenase (prostaglandin endoperoxide synthase) enzyme, which is responsible for the formation of various biologically active pain, fever, and inflammatory mediators. These include prostaglandins, prostacyclin, thromboxane, and arachidonic acid [4, 5].

Mechanism of action

Loxoprofen is a prodrug of mefenamic acid and an inhibitor of the cyclooxygenase. Cyclooxygenase (COX) is present in 2 forms, including COX 1 and COX 2. Loxoprofen, a prodrug, is converted to its trans-alcohol active metabolite, by reduction of its cyclopentanone moiety[7].

Mefenamic acid, the active metabolite of Loxoprofen, is a powerful inhibitor of prostaglandin synthesis in vitro. Prostaglandins potentiate the action of bradykinin, which induces the sensation of pain[5].

COX 1 is present in human cells and is constitutively released, performing cellular housekeeping functions such as mucus production and platelet aggregation [5]. COX 2 is induced in human cells post-injury or other stimuli, and is triggered to appear in large quantities at the sites of injury/stimuli [5].

The mechanism of action of Loxoprofen is to inhibit both COX 1 and 2, resulting in the inhibition of the above mediators, relieving symptoms of pain, inflammation, and fever [5].

TargetActionsOrganism
AProstaglandin G/H synthase 2
antagonist
Human
AProstaglandin G/H synthase 1
antagonist
Human
Absorption

Loxoprofen is rapidly and completely absorbed from the GI tract with a bioavailability of 95% [11]. The absorption phase of the medication occurs in the first 4-6 hours after ingestion. Food ingestion with the medication causes a slight decrease in the rate of loxoprofen absorption. [11].

Volume of distribution

Loxoprofen has a volume of distribution of 0.16 L/kg [11].

Protein binding

99% albumin-bound [11]. At doses of loxoprofen greater than 500 mg/day, an increased clearance of the drug occurs, as saturation of plasma protein binding occurs at higher doses [11].

Metabolism

Loxoprofen is a prodrug rapidly converted to its metabolite, mefenamic acid [12].

Route of elimination

50% renal excretion [10]. This drug is 20% - 30% excreted in the stool [7, 10].

Half life

The elimination half-life of Loxoprofen is approximately 15 hours [11].Steady concentration is achieved after 2-3 doses [11].

Clearance

Most of the drug as unchanged loxoprofen, 6-0-desmethyl loxoprofen (less than 1%) and glucuronide or other conjugates (66-92%) [10].

In patients with renal failure, metabolites may accumulate [11].

Toxicity

Adverse effects include anorexia, nausea, vomiting, bleeding, anemia, diahrrea, and constipation [10]. Loxoprofen toxicity may lead to gastrointestinal disturbance (including flatulence, dyspepsia and gastritis) and renal failure [11].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Loxoprofen.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with 5-androstenedione.Experimental, Illicit
AbciximabLoxoprofen may increase the anticoagulant activities of Abciximab.Approved
AcebutololLoxoprofen may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolLoxoprofen may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Loxoprofen.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alendronic acid.Approved
AliskirenLoxoprofen may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Alminoprofen.Experimental
AlprenololLoxoprofen may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Loxoprofen.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Amcinonide.Approved
AmikacinLoxoprofen may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideLoxoprofen may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Aminosalicylic Acid.Approved
AmiodaroneLoxoprofen may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AncrodLoxoprofen may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Loxoprofen.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Antipyrine.Approved, Investigational
Antithrombin III humanLoxoprofen may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Antrafenine.Approved
ApixabanLoxoprofen may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Apocynin.Investigational
ApramycinLoxoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Loxoprofen.Approved, Investigational
ArbekacinLoxoprofen may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinLoxoprofen may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanLoxoprofen may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololLoxoprofen may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineLoxoprofen may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Atamestane.Investigational
AtenololLoxoprofen may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Loxoprofen.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Loxoprofen.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Loxoprofen.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Loxoprofen.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Balsalazide.Approved, Investigational
BecaplerminLoxoprofen may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololLoxoprofen may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinLoxoprofen may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Loxoprofen.Approved
BenorilateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Loxoprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Loxoprofen.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Loxoprofen.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Betamethasone.Approved, Vet Approved
BetaxololLoxoprofen may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Loxoprofen.Approved, Investigational
BevantololLoxoprofen may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Loxoprofen.Approved, Investigational
BisoprololLoxoprofen may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinLoxoprofen may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololLoxoprofen may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bucillamine.Investigational
BucindololLoxoprofen may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bufexamac.Approved, Experimental
BufuralolLoxoprofen may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Loxoprofen.Approved
BupranololLoxoprofen may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Loxoprofen.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Loxoprofen.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Loxoprofen.Approved
CarprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololLoxoprofen may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolLoxoprofen may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Loxoprofen.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Celecoxib.Approved, Investigational
CeliprololLoxoprofen may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinLoxoprofen may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Loxoprofen.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Loxoprofen.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Loxoprofen.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cimicoxib.Investigational
CinoxacinLoxoprofen may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinLoxoprofen may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cisplatin.Approved
Citric AcidLoxoprofen may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Loxoprofen.Vet Approved
CloranololLoxoprofen may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Loxoprofen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Loxoprofen.Experimental
CyclosporineLoxoprofen may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateLoxoprofen may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinLoxoprofen may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidLoxoprofen may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanLoxoprofen may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Delapril.Experimental
DesipramineLoxoprofen may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinLoxoprofen may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Loxoprofen.Approved, Investigational
DextranLoxoprofen may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinLoxoprofen may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Loxoprofen.Approved, Vet Approved
DicoumarolLoxoprofen may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Loxoprofen.Approved
DihydrostreptomycinLoxoprofen may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Loxoprofen.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Loxoprofen.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Loxoprofen.Approved
DrospirenoneLoxoprofen may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Loxoprofen is combined with E-6201.Investigational
Edetic AcidLoxoprofen may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanLoxoprofen may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Enalaprilat.Approved
EnoxacinLoxoprofen may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinLoxoprofen may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Loxoprofen.Experimental
EpanololLoxoprofen may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Loxoprofen.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Loxoprofen.Experimental
EplerenoneLoxoprofen may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Loxoprofen.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Loxoprofen.Approved
EquileninThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Equilin.Approved
EsatenololLoxoprofen may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololLoxoprofen may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Loxoprofen.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ethenzamide.Experimental
Ethyl biscoumacetateLoxoprofen may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Loxoprofen.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Loxoprofen.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Loxoprofen.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Loxoprofen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Loxoprofen.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Feprazone.Experimental
Ferulic acidLoxoprofen may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Loxoprofen.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fish oil.Approved, Nutraceutical
FleroxacinLoxoprofen may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Loxoprofen.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fludrocortisone.Approved, Investigational
FluindioneLoxoprofen may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineLoxoprofen may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Loxoprofen.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Loxoprofen.Approved, Nutraceutical, Vet Approved
FondaparinuxLoxoprofen may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumLoxoprofen may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Loxoprofen.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Fosinopril.Approved
FramycetinLoxoprofen may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Loxoprofen.Approved, Vet Approved
GabexateLoxoprofen may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinLoxoprofen may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinLoxoprofen may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Loxoprofen.Approved, Withdrawn
GemifloxacinLoxoprofen may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinLoxoprofen may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinLoxoprofen may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ALoxoprofen may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinLoxoprofen may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Loxoprofen is combined with HE3286.Investigational
HeparinLoxoprofen may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Higenamine.Investigational
HydralazineLoxoprofen may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Loxoprofen.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Loxoprofen.Approved, Investigational
Hygromycin BLoxoprofen may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Loxoprofen.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Loxoprofen.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Icosapent.Approved, Nutraceutical
IdraparinuxLoxoprofen may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Loxoprofen.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Loxoprofen.Approved
IndenololLoxoprofen may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Loxoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Loxoprofen.Approved, Investigational
IsepamicinLoxoprofen may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Loxoprofen.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Istaroxime.Investigational
KanamycinLoxoprofen may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Loxoprofen.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Loxoprofen.Approved
LabetalolLoxoprofen may decrease the antihypertensive activities of Labetalol.Approved
LandiololLoxoprofen may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Loxoprofen.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Loxoprofen.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Loxoprofen.Approved, Investigational
LepirudinLoxoprofen may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanLoxoprofen may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololLoxoprofen may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololLoxoprofen may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinLoxoprofen may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Loxoprofen.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Loxoprofen.Approved
LomefloxacinLoxoprofen may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Loxoprofen.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Loteprednol.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Loxoprofen.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Loxoprofen.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Loxoprofen is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mefenamic acid.Approved
MelagatranLoxoprofen may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Meloxicam.Approved, Vet Approved
MepindololLoxoprofen may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Loxoprofen.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Loxoprofen.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Loxoprofen.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Methylprednisolone.Approved, Vet Approved
MetipranololLoxoprofen may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Loxoprofen.Approved
MetoprololLoxoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinLoxoprofen may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Loxoprofen.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Loxoprofen.Approved
MizoribineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Loxoprofen.Approved
MoxifloxacinLoxoprofen may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Loxoprofen.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loxoprofen.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Nabumetone.Approved
NadololLoxoprofen may decrease the antihypertensive activities of Nadolol.Approved
NadroparinLoxoprofen may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatLoxoprofen may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Loxoprofen.Approved
Nalidixic AcidLoxoprofen may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Loxoprofen is combined with NCX 1022.Investigational
NeamineLoxoprofen may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololLoxoprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinLoxoprofen may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinLoxoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Nepafenac.Approved, Investigational
NetilmicinLoxoprofen may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Nitroaspirin.Investigational
NorfloxacinLoxoprofen may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinLoxoprofen may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Loxoprofen.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Loxoprofen.Approved
OlsalazineLoxoprofen may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Loxoprofen is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Orgotein.Vet Approved
OtamixabanLoxoprofen may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Oxaprozin.Approved
Oxolinic acidLoxoprofen may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololLoxoprofen may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Loxoprofen.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Parecoxib.Approved
ParomomycinLoxoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Parthenolide.Approved, Investigational
PazufloxacinLoxoprofen may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinLoxoprofen may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololLoxoprofen may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateLoxoprofen may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateLoxoprofen may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Perindopril.Approved
PhenindioneLoxoprofen may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonLoxoprofen may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Loxoprofen.Approved, Investigational
PindololLoxoprofen may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidLoxoprofen may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Loxoprofen.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Loxoprofen.Approved, Investigational
Piromidic acidLoxoprofen may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorLoxoprofen may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinLoxoprofen may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Loxoprofen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pomalidomide.Approved
Potassium CitrateLoxoprofen may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololLoxoprofen may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Loxoprofen.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Loxoprofen can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Propacetamol.Approved, Investigational
PropafenoneLoxoprofen may decrease the antihypertensive activities of Propafenone.Approved
PropranololLoxoprofen may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Loxoprofen.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Loxoprofen.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Loxoprofen.Vet Approved
Protein CLoxoprofen may increase the anticoagulant activities of Protein C.Approved
Protein S humanLoxoprofen may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeLoxoprofen may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinLoxoprofen may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Loxoprofen.Investigational
PuromycinLoxoprofen may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Loxoprofen.Approved
RamiprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinLoxoprofen may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinLoxoprofen may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Risedronate.Approved, Investigational
RivaroxabanLoxoprofen may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinLoxoprofen may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinLoxoprofen may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Loxoprofen.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Loxoprofen.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Loxoprofen.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Loxoprofen.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Loxoprofen.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Loxoprofen.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Serrapeptase.Investigational
SisomicinLoxoprofen may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinLoxoprofen may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateLoxoprofen may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Loxoprofen.Approved
SotalolLoxoprofen may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinLoxoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Spirapril.Approved
SpironolactoneLoxoprofen may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Loxoprofen.Investigational
StreptomycinLoxoprofen may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Sulindac.Approved, Investigational
SulodexideLoxoprofen may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Loxoprofen.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Suxibuzone.Experimental
TacrolimusLoxoprofen may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Loxoprofen.Approved
TalinololLoxoprofen may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Loxoprofen.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Loxoprofen.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Loxoprofen.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Loxoprofen.Approved, Investigational
TemafloxacinLoxoprofen may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tepoxalin.Vet Approved
TerbutalineLoxoprofen may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Loxoprofen.Approved
TertatololLoxoprofen may decrease the antihypertensive activities of Tertatolol.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololLoxoprofen may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tixocortol.Approved, Withdrawn
TobramycinLoxoprofen may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Loxoprofen.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Loxoprofen.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Loxoprofen.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Loxoprofen.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Triamcinolone.Approved, Vet Approved
TriamtereneLoxoprofen may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Loxoprofen.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Trolamine salicylate.Approved
TrovafloxacinLoxoprofen may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinLoxoprofen may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Loxoprofen.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Loxoprofen.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Loxoprofen.Approved
WarfarinLoxoprofen may increase the anticoagulant activities of Warfarin.Approved
XimelagatranLoxoprofen may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Loxoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Loxoprofen.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Loxoprofen.Withdrawn
Food Interactions
Not Available

References

General References
  1. Koup JR, Tucker E, Thomas DJ, Kinkel AW, Sedman AJ, Dyer R, Sharoky M: A single and multiple dose pharmacokinetic and metabolism study of meclofenamate sodium. Biopharm Drug Dispos. 1990 Jan-Feb;11(1):1-15. [PubMed:2322633]
  2. Loxoprofen [Link]
  3. MIMS LOXOPROFEN [Link]
  4. Mechanism of action of non steroidal anti-inflammatory drugs [Link]
  5. Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks [Link]
  6. Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation [Link]
  7. Comparison of Pharmacokinetics between Loxoprofen and Its Derivative with Lower Ulcerogenic Activity, Fluoro-loxoprofen [Link]
  8. Comparison of Pharmacokinetics between Loxoprofen and Its Derivative with Lower Ulcerogenic Activity, Fluoro-loxoprofen [Link]
  9. Aspirin, Non-Aspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and risk of ovarian cancer [Link]
  10. LOXOPROFEN [Link]
  11. Loxoprofen Sodium [Link]
  12. Roxonin [Link]
External Links
Human Metabolome Database
HMDB0041920
KEGG Drug
D08149
PubChem Compound
3965
PubChem Substance
310265119
ChemSpider
3828
BindingDB
50140320
ChEBI
76172
ChEMBL
CHEMBL19299
PharmGKB
PA166049180
Wikipedia
Loxoprofen

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Volunteers1
2CompletedTreatmentChronic Non-specific, Uncomplicated Neck Pain1
2RecruitingTreatmentRheumatoid Arthritis1
2Unknown StatusTreatmentChronic Low Back Pain (CLBP)1
3CompletedTreatmentAcute Upper Respiratory Infection / Fevers1
3CompletedTreatmentLow Back Pain (LBP)1
3CompletedTreatmentPain1
3CompletedTreatmentPain / Traumas1
4CompletedTreatmentHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)108.5 - 111[L1225]
boiling point (°C)220.7[L1225]
water solubility47 mg/mL[L1225]
Predicted Properties
PropertyValueSource
Water Solubility0.0663 mg/mLALOGPS
logP2.99ALOGPS
logP3.35ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)4.19ChemAxon
pKa (Strongest Basic)-7.4ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity68.8 m3·mol-1ChemAxon
Polarizability27.08 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
Monocyclic monoterpenoids / Aromatic monoterpenoids / Benzene and substituted derivatives / Cyclic ketones / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
2-phenylpropanoic-acid / P-cymene / Aromatic monoterpenoid / Monocyclic monoterpenoid / Monoterpenoid / Monocyclic benzene moiety / Benzenoid / Ketone / Cyclic ketone / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monocarboxylic acid, cyclopentanones (CHEBI:76172)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. KEGG DRUG: Loxoprofen [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Loxoprofen sodium hydrate [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Loxoprofen sodium hydrate [Link]

Drug created on October 20, 2015 15:51 / Updated on June 02, 2018 09:36